Dr Reddys Laboratories (RDY) Other Non-Current Assets (2009 - 2026)

Dr Reddys Laboratories (RDY) posted quarterly Other Non-Current Assets of $13.0 million for Q1 2026, up 8.33% year-on-year from $12.0 million in Q1 2025, and up 8.33% on a QoQ basis from $12.0 million in Q1 2025.

Dr Reddys Laboratories (RDY) Other Non-Current Assets (2009 - 2026) Analysis & Trends

Dr Reddys Laboratories (RDY) has reported Other Non-Current Assets for 10 consecutive years, with $13.0 million the latest figure, recorded in Q1 2026.

  • Quarterly Other Non-Current Assets rose 8.33% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 8.33% YoY) and the FY2026 annual result came in at $13.0 million, up 8.33% from the prior year.
  • Other Non-Current Assets rose to $13.0 million in Q1 2026 per RDY's latest filing, from $12.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for RDY reached as high as $20.0 million in Q1 2024 and fell as low as $10.0 million in Q1 2023.
  • A 5-year average of $13.4 million and a median of $12.0 million in 2022 frame the typical range for Other Non-Current Assets.
  • Annual changes were most pronounced in 2024 — Other Non-Current Assets soared 100.0% — and 2025, when it tumbled 40.0%.
  • Year by year, Other Non-Current Assets stood at $12.0 million in 2022, then slipped by 16.67% to $10.0 million in 2023, then surged by 100.0% to $20.0 million in 2024, then slumped by 40.0% to $12.0 million in 2025, then rose by 8.33% to $13.0 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods registered $13.0 million, $12.0 million, and $20.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 49.22 Mn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 1.79 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 351.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 491.06 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 233.20 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 1.11 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 73.60 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 295.00 Mn
10 Dr Reddys Laboratories 9.82 Bn 9.66 Bn - 13.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 13.00 Mn
Mar 31, 2025 12.00 Mn
Mar 31, 2024 20.00 Mn
Mar 31, 2023 10.00 Mn
Mar 31, 2022 12.00 Mn
Mar 31, 2021 11.00 Mn
Mar 31, 2020 11.00 Mn
Mar 31, 2019 14.00 Mn
Mar 31, 2018 16.00 Mn
Dec 31, 2009 4.00 Mn
Sep 30, 2009 4.00 Mn
Jun 30, 2009 4.00 Mn